Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)

R. C. Coombes; P. D. Badman; J. P. Lozano-Kuehne; X. Liu; I. R. Macpherson; I. Zubairi; R. D. Baird; N. Rosenfeld; J. Garcia-Corbacho; N. Cresti; R. Plummer; A. Armstrong; R. Allerton; D. Landers; H. Nicholas; L. McLellan; A. Lim; F. Mouliere; O. E. Pardo; V. Ferguson; M. J. Seckl

doi:https://doi.org/10.1038/s41467-023-35969-4

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)

R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, V. FergusonM. J. Seckl

Pathology (VUmc)

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list. Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the article.

Original language	English
Article number	260
Journal	Nature communications
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/s41467-023-35969-4
Publication status	Published - 1 Dec 2023

Access to Document

https://doi.org/10.1038/s41467-023-35969-4

Cite this

Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., ... Seckl, M. J. (2023). Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0). Nature communications, 14(1), Article 260. https://doi.org/10.1038/s41467-023-35969-4

@article{2e24eea9c5384698a2feb42f4af64dd7,

title = "Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)",

abstract = "In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list. Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the article.",

author = "Coombes, {R. C.} and Badman, {P. D.} and Lozano-Kuehne, {J. P.} and X. Liu and Macpherson, {I. R.} and I. Zubairi and Baird, {R. D.} and N. Rosenfeld and J. Garcia-Corbacho and N. Cresti and R. Plummer and A. Armstrong and R. Allerton and D. Landers and H. Nicholas and L. McLellan and A. Lim and F. Mouliere and Pardo, {O. E.} and V. Ferguson and Seckl, {M. J.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

month = dec,

day = "1",

doi = "https://doi.org/10.1038/s41467-023-35969-4",

language = "English",

volume = "14",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

Coombes, RC, Badman, PD, Lozano-Kuehne, JP, Liu, X, Macpherson, IR, Zubairi, I, Baird, RD, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, OE, Ferguson, V & Seckl, MJ 2023, 'Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)', Nature communications, vol. 14, no. 1, 260. https://doi.org/10.1038/s41467-023-35969-4

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0). / Coombes, R. C.; Badman, P. D.; Lozano-Kuehne, J. P. et al.
In: Nature communications, Vol. 14, No. 1, 260, 01.12.2023.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Author Correction

T2 - Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)

AU - Coombes, R. C.

AU - Badman, P. D.

AU - Lozano-Kuehne, J. P.

AU - Liu, X.

AU - Macpherson, I. R.

AU - Zubairi, I.

AU - Baird, R. D.

AU - Rosenfeld, N.

AU - Garcia-Corbacho, J.

AU - Cresti, N.

AU - Plummer, R.

AU - Armstrong, A.

AU - Allerton, R.

AU - Landers, D.

AU - Nicholas, H.

AU - McLellan, L.

AU - Lim, A.

AU - Mouliere, F.

AU - Pardo, O. E.

AU - Ferguson, V.

AU - Seckl, M. J.

PY - 2023/12/1

Y1 - 2023/12/1

N2 - In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list. Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the article.

AB - In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list. Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85146405878&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41467-023-35969-4

DO - https://doi.org/10.1038/s41467-023-35969-4

M3 - Comment/Letter to the editor

C2 - 36650166

SN - 2041-1723

VL - 14

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 260

ER -

Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I et al. Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0). Nature communications. 2023 Dec 1;14(1):260. doi: https://doi.org/10.1038/s41467-023-35969-4

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)

Abstract

Access to Document

Other files and links

Cite this